GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Forest Laboratories Inc (FRA:FQX) » Definitions » ROC (Joel Greenblatt) %

Forest Laboratories (FRA:FQX) ROC (Joel Greenblatt) % : -15.22% (As of Mar. 2014)


View and export this data going back to . Start your Free Trial

What is Forest Laboratories ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Forest Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2014 was -15.22%.

The historical rank and industry rank for Forest Laboratories's ROC (Joel Greenblatt) % or its related term are showing as below:

FRA:FQX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -23.07   Med: 88.52   Max: 192.34
Current: 17.44

During the past 13 years, Forest Laboratories's highest ROC (Joel Greenblatt) % was 192.34%. The lowest was -23.07%. And the median was 88.52%.

FRA:FQX's ROC (Joel Greenblatt) % is not ranked
in the Drug Manufacturers industry.
Industry Median: 8.425 vs FRA:FQX: 17.44

Forest Laboratories's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Forest Laboratories ROC (Joel Greenblatt) % Historical Data

The historical data trend for Forest Laboratories's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forest Laboratories ROC (Joel Greenblatt) % Chart

Forest Laboratories Annual Data
Trend Mar05 Mar06 Mar07 Mar08 Mar09 Mar10 Mar11 Mar12 Mar13 Mar14
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 139.54 189.59 181.50 -12.22 14.63

Forest Laboratories Quarterly Data
Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.92 22.09 50.63 12.75 -15.22

Competitive Comparison of Forest Laboratories's ROC (Joel Greenblatt) %

For the Drug Manufacturers - Specialty & Generic subindustry, Forest Laboratories's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Forest Laboratories's ROC (Joel Greenblatt) % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Forest Laboratories's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Forest Laboratories's ROC (Joel Greenblatt) % falls into.



Forest Laboratories ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2013 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(270.013 + 319.741 + 336.626) - (759.222 + 0 + 0)
=167.158

Working Capital(Q: Mar. 2014 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(417.065 + 442.956 + 564.768) - (1092.214 + 0 + 0)
=332.575

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Forest Laboratories for the quarter that ended in Mar. 2014 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2014 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2013  Q: Mar. 2014
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-80.448/( ( (288.768 + max(167.158, 0)) + (268.822 + max(332.575, 0)) )/ 2 )
=-80.448/( ( 455.926 + 601.397 )/ 2 )
=-80.448/528.6615
=-15.22 %

Note: The EBIT data used here is four times the quarterly (Mar. 2014) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Forest Laboratories  (FRA:FQX) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Forest Laboratories ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Forest Laboratories's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Forest Laboratories (FRA:FQX) Business Description

Traded in Other Exchanges
N/A
Address
Forest Laboratories, Inc. is a Delaware corporation organized in 1956. The Company develops, manufactures and sells branded forms of ethical drug products most of which require a physician's prescription. The Company's most important United States products are marketed directly, or 'detailed,' to physicians by its salesforces. It emphasizes detailing to physicians of those branded ethical drugs which have the most potential for growth and benefit to patients. The Company also develops and introduces new products, including products developed in collaboration with licensing partners. The Company's products include those developed by it and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. It actively promotes in the United States those branded products which have the most potential for growth and patient benefit, and which enable its salesforces to concentrate on groups of physicians who are high prescribers of its products. Such products include: Lexapro, its SSRI for the treatment of major depression in adults and adolescents and GAD in adults; Namenda, its NMDA antagonist for the treatment of moderate and severe Alzheimer's disease; Bystolic, its beta-blocker for the treatment of hypertension; and Savella, its newest product, an SNRI for the management of fibromyalgia. The Company's United Kingdom and Ireland subsidiaries sell both ethical products and over-the-counter preparations. Their most important products include Sudocrem, a topical preparation for the treatment of diaper rash; Colomycin, an antibiotic used in the treatment of cystic fibrosis; Infacol, used to treat infant colic; and Exorex, used in the treatment of eczema and psoriasis. The pharmaceutical industry is subject to comprehensive government regulation which substantially increases the difficulty and cost incurred in obtaining the approval to market newly proposed drug products and maintaining the approval to market existing drugs.

Forest Laboratories (FRA:FQX) Headlines

No Headlines